Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51858 | 0.86 | KDM4E (0.41) | KMT2AKDM4EALDH1A1MAPK1HSD17B10 | |
| SCHEMBL61188 | 0.86 | TNKS2 (0.50) | KMT2AKDM4EALDH1A1MAPK1HSD17B10 | |
| SCHEMBL3515927 | 0.85 | KDM4E (0.40) | KMT2AKDM4EALDH1A1MAPK1HSD17B10 | |
| SCHEMBL3520029 | 0.85 | KDM4E (0.45) | KMT2AMEN1KDM4EALDH1A1MAPK1 | |
| SCHEMBL50840 | 0.79 | MLLT1 (0.50) | KMT2AMEN1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL83409 | 0.78 | MLLT1 (0.52) | KMT2AMEN1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL51906 | 0.78 | TYMS (0.49) | ALDH1A1HSD17B10 | |
| SCHEMBL3517823 | 0.78 | MEN1 (0.43) | KMT2AMEN1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL3518208 | 0.78 | BCHE (0.42) | KDM4EALDH1A1HSD17B10TSHRLMNA | |
| SCHEMBL50874 | 0.77 | MMP13 (0.43) | KMT2AMEN1KDM4ETDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309717-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | EISAI INC. (US) | 2012-12-06 | — | — | US | disclosed |
| EP-1633362-B1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | EISAI INC (US) | 2012-09-26 | — | — | EP | disclosed |
| US-8129382-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100256095-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | EISAI INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7750008-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | EISAI INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090298837-A1 | poly(ADP-ribose) polymerase (PARP) inhibitors such as 9-[(Hydrozinooxy)carbonyl]-2,7-dihydro-6-methoxy 3H-pyrido-[4,3,2-de]phthalazin-3-one, used for treating neuron tissue damage resulting from ischemia and reperfusion injury, depression, inflammatory bowel disorders, arthritis, gout, pain and sepsis | EISAI CORPORATION OF NORTH AMERICA (US) | 2009-12-03 | — | — | US | disclosed |
| US-7601719-B2 | Administering temozolomide; poly/adp-ribose/polymerase (PARP) inhibitors; melanoma, lymphoma, glioblastoma multiforme | EISAI CORPORATION OF NORTH AMERICA (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090088407-A1 | Administering temozolomide; poly/adp-ribose/polymerase (PARP) inhibitors; melanoma, lymphoma, glioblastoma multiforme | MGI GP, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-7456178-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | MGI GP, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1633362-A4 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | MGI GP INC (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20080058325-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | MGI GP, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-7268138-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | MGI GP, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1633362-A2 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | MGI GP, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050020595-A1 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | EISAI INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004105700-A2 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | GUILDFORD PHARMACEUTICALS, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298837-A1 | poly(ADP-ribose) polymerase (PARP) inhibitors such as 9-[(Hydrozinooxy)carbonyl]-2,7-dihydro-6-methoxy 3H-pyrido-[4,3,2-de]phthalazin-3-one, used for treating neuron tissue damage resulting from ischemia and reperfusion injury, depression, inflammatory bowel disorders, arthritis, gout, pain and sepsis | PARP1, PARP2, NLRP3 | KMT2A 2073/4885MEN1 4831/4885KDM4E 2880/4885 |
| US-20080058325-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | KMT2A 1504/4885MEN1 3639/4885KDM4E 1640/4885 |
| US-20050020595-A1 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | PARP1, PARP2, PARP3 | KMT2A 1388/4885MEN1 3554/4885KDM4E 1571/4885 |
| US-20120309717-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | KMT2A 1388/4885MEN1 3554/4885KDM4E 1571/4885 |
| US-20090088407-A1 | Administering temozolomide; poly/adp-ribose/polymerase (PARP) inhibitors; melanoma, lymphoma, glioblastoma multiforme | PARP1, PARP2, PARP11 | KMT2A 209/4885MEN1 348/4885KDM4E 297/4885 |
| US-20100256095-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | KMT2A 1388/4885MEN1 3554/4885KDM4E 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.